Opthea Limited (OPT)
Company Description
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.
The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases.
The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.
Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Country | AU |
IPO Date | Oct 16, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 33 |
CEO | Dr. Frederic Guerard M.S., Pharm.D. |
Contact Details
Address: 650 Chapel Street South Yarra, VIC AU | |
Website | https://www.opthea.com |
Stock Details
Ticker Symbol | OPT |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001815620 |
CUSIP Number | 68386J208 |
ISIN Number | US68386J2087 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer |
Thomas Charles Reilly | Chief Financial Officer |
Anand Sundaram | Vice President Marketing |
Dr. Arshad M. Khanani M.A., M.D. | Chief Medical Advisor & Chairman of Medical Advisory Board |
Dr. Dayong Li Ph.D. | Senior Vice President, Biometrics |
Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs |
Dr. Julie Clark M.D., M.S. | Senior Vice President of Clinical Development |
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder & Chief Innovation Officer |
Jen Watts | Vice President Global Clinical Operations |
Kevin Bitter | Vice President of Strategy & Corporate Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 31, 2025 | 6-K | Filing |
Mar 24, 2025 | 6-K | Filing |
Mar 03, 2025 | 6-K | Filing |
Feb 28, 2025 | 6-K | Filing |
Feb 26, 2025 | 6-K | Filing |
Feb 18, 2025 | 6-K | Filing |
Feb 07, 2025 | 6-K | Filing |
Feb 06, 2025 | 6-K | Filing |
Jan 28, 2025 | 6-K | Filing |
Jan 13, 2025 | 6-K | Filing |